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Research Correspondence
Single Exhaled Breath Metabolomic
Analysis Identifies Unique Breathprint inHeart FailureTo the Editor: Acute decompensated heart failure (ADHF) is the
ost common indication for hospital admission, particularly in the
lderly, yet the identification of those with impending decompen-
ation using conventional clinical methods is unreliable and fre-
uently leaves insufficient lag time for therapeutic interventions
1). Exhaled breath constitutes a complex mixture of hundreds of
olatile organic compounds (VOCs) that could potentially be used
s a safe and noninvasive method of diagnostic and therapeutic
onitoring (2). Previous research studies have identified elevated
cetone, pentane, and nitric oxide levels in exhaled breath in the
etting of HF correlated with disease severity (3–5). Selected
ion-flow tube mass-spectrometry (SIFT-MS) combines a fast flow
tube technique with quantitative mass spectrometry that is ideally
suited for exhaled breath analysis because it allows for the analysis
of small and humid samples without the need for cumbersome
sample preparation or calibration (6). Scan times are relatively
brief, thus facilitating high throughput and serial comparisons.
Figure 1 Canonical Discriminant Analysis: ADHF Versus Non-HF
Canonical discriminant analysis using 5 selected mass scanning ion peaks was
subjects (blue) and 16 controls (red). This ADHF “breathprint” was then used
misclassifications.Using this technology, we conducted a prospective, single-center
cohort study to assess the feasibility of exhaled breath analysis to
identify patients admitted for ADHF. The study protocol was
approved by the Cleveland Clinic Institutional Review Board. We
recruited 25 consecutive patients admitted with ADHF as their
primary diagnosis (mean left ventricular ejection fraction 27 
13%, median N-terminal pro–B-type natriuretic peptide level 954
pg/ml) and a control group of 16 subjects admitted with non-
ADHF cardiovascular diagnoses and who had no clinical evidence
of systemic or venous congestion at the time of enrollment.
Indications for hospitalization in the control group included
unstable angina or non–ST-segment elevation myocardial infarc-
tion (6 of 16), conduction disorders (3 of 16), hypertensive
emergency (3 of 16), atrial tachyarrhythmia (2 of 16), or stable angina
(2 of 16). All analyses were performed using JMP Pro 9.0 (SAS
Institute, Cary, North Carolina). As expected, there were significant
(p 0.01) baseline differences in the frequency of hypertension (54%
trols
rmed in a training cohort of 25 acute decompensated heart failure (ADHF)
ssify an independent validation cohort of 36 ADHF subjects (green) with noCon
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April 2, 2013:1461–8vs. 100%) and baseline estimated glomerular filtration rate (68  43
l/min/1.73 m2 vs. 102  44 ml/min/1.73 m2), which were signif-
cantly worse in the ADHF versus control group. Nevertheless, there
ere no significant differences between groups in age, body mass
ndex, or several comorbidities (i.e., diabetes mellitus, chronic obstruc-
ive pulmonary disease, active smoking) theorized to result in altera-
ions in the exhaled metabolome.
After written informed consent was obtained, exhaled breath
amples were collected within 24 h of hospital admission and
ollowing an 8-h fast and before the administration of morning
harmacotherapy. Samples were collected after tap water mouth rinse
o minimize and standardize the contribution of the aerodigestive
ract. Patients provided a single exhaled vital capacity into a sterile
outhpiece while attempting to maintain an exhaled pressure of 15
illibars. All breath analyses were performed within 2 h of collection
sing a VOICE200 SIFT-MS instrument (Syft Technologies,
hristchurch, New Zealand). Pre-specified quantitative assessment of
cetone and pentane was performed using the SIFT-MS technique.
ample collection was well tolerated even among patients with disease
everity warranting intensive care unit admission and invasive hemo-
ynamic monitoring. Confirming previous reports (3,4), we observed
ncreased exhaled acetone (median [interquartile range]: 811 [256 to
974] ppb vs. 187 [115 to 572] ppb, p  0.01) and pentane (40 [20
o 74] ppb vs. 22 [14 to 36] ppb, p  0.03) levels in ADHF versus
ontrol groups. In addition, mass scanning of ion products for H3O
,
2
, and NO from 14 to 200 atomic mass units was performed, and
stepwise variable selection was used to identify 5 ion peaks that were
incorporated into a canonical discriminant analysis model that suc-
cessfully distinguished ADHF from control patients (2 log likeli-
hood 0.038; Wilks’ Lambda 0.102 [p  0.0001]) (Fig. 1). This
“breathprint” was then tested in an independent validation cohort of
36 consecutive ADHF subjects with identical enrollment criteria to
the derivation cohort. The discriminant analysis model correctly
classified all subjects with no misclassifications (Fig. 1).
The exhaled metabolome is a temporally dynamic complex
mixture, and therefore breath analysis is highly susceptible to the
confounding effects of timing and context of sample collection. In
addition, methods of metabolomic data analysis (e.g., data reduc-
tion techniques) are still being formalized and will need to be
refined to facilitate reproducibility and generalizability of future
studies. Results of this study are limited by the small sample size,
and larger prospective studies are needed to validate these results.
Nevertheless, our findings demonstrate the feasibility of single
exhaled breath analysis in ADHF. In addition, we validated the
previously reported alterations in acetone and pentane VOC
concentrations in ADHF, and provided pilot evidence to support
the hypothesis that a unique ADHF breathprint exists using
SIFT-MS technology. Once a specific VOC or panel of VOCs is
identified, highly sensitive and specific solid-state sensors can be
integrated into portable detectors. Like conventionally available
exhaled breath sensors, the promise of this technology lies in the
potential for point-of-care and ambulatory monitoring and screen-
ing. Future studies in exhaled breath metabolomics are needed to
accelerate progress in the field of cardiovascular medicine.
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Letters to the Editor
Colchicine After Pulmonary Vein
Isolation: Is Inflammation the
New Anti-Arrhythmic Target
We have read with interest the study by Deftereos et al. (1) aimed
at testing the role of colchicine in preventing atrial fibrillation (AF)
recurrences in patients with recurrent paroxysmal AF who under-
